Clinical trial / 2018
In advanced Parkinson's disease, Mucuna pruriens showed similar efficacy to levodopa/carbidopa when tolerated, but half of patients discontinued due to side effects.
Fourteen Parkinson's disease patients with motor fluctuations and dyskinesias received Mucuna pruriens (MP) powder and levodopa/carbidopa (LD/CD) in a randomized crossover design over 16 weeks. Seven patients (50%) discontinued MP prematurely due to gastrointestinal side effects (n=4) or progressive worsening of motor performance (n=3), whereas no patients discontinued during the LD/CD phase. In patients who tolerated MP, the clinical response was similar to LD/CD across all efficacy outcomes. Dropouts later tolerated an MP supernatant water formulation in a study extension (median 16 weeks).
- Study type
- 16-week randomized crossover noninferiority pilot study
- Who was studied
- 14 Parkinson's disease patients with motor fluctuations and dyskinesias
- What was measured
- Changes in quality of life, motor and non-motor symptoms, good mobility time, tolerability, adverse events, lab indices, and ECG
THE PAPER
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G. Parkinsonism Relat Disord, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.